HMB-001

DRUG2 trials

Sponsors

Hemab ApS

Conditions

Glanzmann Thrombasthenia

Phase 1

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

Active, not recruitingNCT06211634

Hemab ApSGlanzmann Thrombasthenia

Start: 2022-12-13End: 2027-08-31Target: 57Updated: 2025-12-24

A Phase 1/2, First-in-Human, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia

RecruitingCTIS2023-505995-31-00

Hemab ApSGlanzmann Thrombasthenia

Start: 2024-05-03Target: 20Updated: 2025-12-19

Related Papers

A Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sutacimig for prophylaxis in glanzmann thrombasthenia: A trial in progress

Blood2025-11-03

Sutacimig, a novel bispecific antibody for prophylactic treatment of glanzmann thrombasthenia: Analysis of a Phase 2 study

Blood2025-11-03

A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Blood2024-11-05